Abstract
We report the case of a patient with scleromyxedema with abnormal monoclonal gammaglobulin of the kappa type who was treated with melphalan (Alkeran®), an alkylating agent. After nine and one-half years of therapy, the patient showed myelomonocytic leukemia. The risk of secondary malignancies must be considered when weighing the benefits and risks of melphalan treatment.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 219-223 |
| Number of pages | 5 |
| Journal | Cutis |
| Volume | 39 |
| Issue number | 3 |
| State | Published - 1987 |
All Science Journal Classification (ASJC) codes
- Dermatology